导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.89% | 3502/4773 |
| 近一周 | -2.74% | 4215/5465 |
| 近一月 | -3.59% | 2664/5421 |
| 近一季 | 1.79% | 668/5231 |
| 近半年 | -6.52% | 3214/4920 |
| 近一年 | -5.05% | 3160/4394 |
| 近两年 | 17.79% | 2686/2954 |
| 近三年 | 4.04% | 1861/2253 |
| 成立以来 | 46.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.18% 2708/4961 |
-8.25% 3864/5312 |
- - |
- - |
| 2025 | 5.92% 2980/4813 |
-2.39% 2881/3635 |
-1.04% 3098/4076 |
8.76% 3399/4524 |
0.83% 1734/4813 |
| 2024 | 13.07% 1184/3463 |
5.36% 369/2808 |
-2.92% 1277/3014 |
18.57% 986/3129 |
-6.76% 2700/3463 |
| 2023 | -4.55% 684/2656 |
4.12% 1045/2280 |
-3.53% 819/2385 |
2.23% 245/2515 |
-7.03% 2022/2655 |
| 2022 | -6.63% 132/2207 |
-5.62% 196/1919 |
6.54% 675/2016 |
-5.85% 88/2113 |
-1.38% 1697/2208 |
| 2021 | -9.12% 1071/1822 |
-5.62% 942/1255 |
-2.59% 1218/1330 |
-6.67% 978/1466 |
5.91% 256/1822 |
| 2020 | 44.12% 231/1250 |
-11.02% 812/1028 |
16.31% 446/1067 |
19.56% 68/1164 |
16.48% 167/1184 |
| 2019 | - - |
- - |
- - |
- - |
4.79% 780/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信中证红利潜力指数A VS. 长安沪深300非周期A(740101) |